Investment Information

With transparent disclosure of information and communication with markets,
we will grow along with shareholders.

HanAll's Partner HBM Announces Positive Topline Results from Phase 2 of Batoclimab in MG

Date|2021-07-07

Related Data

HanAll Biopharma (KRX: 009420.KS) today announced that its partner for HL161 (batoclimab) & HL036 (tanfanercept)​, Harbour BioMed, reported positive topline results from Phase 2 of batoclimab in MG.

 

- HBM press release link: https://www.harbourbiomed.com/news/157.html

​

 

NextHanAll's Partner HBM Announces Last Patient Dosing of Phase 1b/2a of Batoclimab in NMOSD

PrevHanAll Biopharma Reports First Quarter 2021 Financial Results

List